Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
India Cross-Border Business and Investment ForumMonday, February 2, 2026 | Wednesday, February 4, 2026 | Friday, February 6, 2026How Shareholder Activism Fared in 2025January 29, 2026Sidley Represents Glenfarne as Principal Project Counsel on Alaska LNGJanuary 29, 2026Sidley Represents Sleep Number Corporation in Strategic Partnership With Travis KelceJanuary 29, 2026Sidley Advises FAS Group on I Squared Capital’s Investment into FAS RenewablesJanuary 29, 2026Sidley Represents Athene in Its US$9 Billion Acquisition of Apollo’s Commercial Real Estate Loan PortfolioJanuary 28, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory